Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?
Tally Is Behind Recent Years
Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.
